aestheticmedguideAestheticMedGuide
Injectables

Is Renuva FDA-Approved as a Dermal Filler? HCT/P Tissue Rules Are Not a PMA

Renuva is a US HCT/P adipose matrix, not an FDA-approved dermal filler. Clinic FDA-approved-filler claims, a January 2021 list, and Renuvion 510(k) hits are not a PMA.

Ran Chen
Ran Chen
34 min read · Published · Evidence-based

When patients explore non-surgical options to restore facial hollows, fill cellulite dimples, or smooth post-liposuction contour irregularities, commercial medical spa websites and plastic surgery blogs frequently describe Renuva as an "FDA-approved dermal filler" or an "FDA-approved injectable." In some marketing copy, clinics claim that in January 2021 Renuva was added to an official list of FDA-approved injectable products. In other instances, Google search results display 510(k) premarket clearance records for similarly named aesthetic devices, leading prospective patients to assume that Renuva has cleared the same premarket safety and efficacy hurdles as Juvéderm, Restylane, or Sculptra.

The regulatory answer is definitive: No. Renuva is not an FDA-approved dermal filler in the United States.

Renuva (Renuva Allograft Adipose Matrix, manufactured by MTF Biologics / Musculoskeletal Transplant Foundation) is regulated in the United States not as a medical device or pharmaceutical drug, but as a Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) under Section 361 of the Public Health Service Act (PHS Act) and Title 21 of the Code of Federal Regulations, Part 1271 (21 CFR Part 1271).

Under this domestic framework, 361 HCT/Ps that satisfy strict criteria—minimal manipulation, homologous use only, no combination with unapproved active agents, and no systemic effect—do not undergo prospective premarket clinical review. They do not submit a Premarket Approval (PMA) application to the FDA Center for Devices and Radiological Health (CDRH), they do not receive an FDA approval order or a Product Code LMH dermal-implant classification, and they do not generate a public Summary of Safety and Effectiveness Data (SSED).

A comprehensive census of the FDA CDRH Premarket Approval database through 10 July 2026—comprising 1,046 Class III aesthetic dermal implant records under Product Code LMH and 2 hand-augmentation records under Product Code PKY—finds zero records matching Renuva, allograft adipose matrix, MTF Biologics, Musculoskeletal Transplant Foundation, AlloClae, or Lipoderma. Furthermore, the official FDA-Approved Dermal Fillers materials list recognizes only four material classes: hyaluronic acid (HA), calcium hydroxylapatite (CaHA), poly-L-lactic acid (PLLA), and polymethylmethacrylate (PMMA) with bovine collagen. Allograft adipose matrix is absent from this list.

This guide provides a rigorous analysis of Renuva's actual U.S. regulatory standing. We examine the legal boundaries of Section 361 HCT/P regulation versus a Class III device PMA, audit the specific manufacturer instructions and contraindications in MTF Biologics' Package Insert PI-113, dissect why prominent clinic websites claim FDA approval, expose search-engine confusion with Apyx Medical's Renuvion plasma device, compare Renuva to legitimate FDA-approved biostimulators, and define who should decline a Renuva quote.

Direct Summary: Renuva U.S. Regulatory Status at a Glance

Feature / Question Regulatory & Clinical Fact
Product Name Renuva (Renuva Allograft Adipose Matrix). Commercial tissue codes: AP0101 (1.5 cc) and AP0103 (3 cc).
Manufacturer & Tissue Bank MTF Biologics (Musculoskeletal Transplant Foundation, Edison, NJ). Consumer portal: myrenuva.com.
Tissue Classification Donated human adipose allograft tissue; aseptically processed extracellular matrix (manufacturer: collagens, proteins, and growth factors). Not terminally sterilized.
U.S. FDA Approval Status NOT FDA-Approved as a Dermal Filler. Renuva holds zero Premarket Approvals (PMA) and zero 510(k) clearances as a soft-tissue dermal filler.
Domestic Regulatory Pathway Marketed under Section 361 of the PHS Act and 21 CFR Part 1271 as a 361 HCT/P overseen by CBER. Operates via establishment registration and donor-screening listing, not premarket approval.
FDA LMH Dermal Implant Census 1,046 total records evaluated through July 2026. Zero records match Renuva, allograft adipose, MTF Biologics, or sibling brand AlloClae.
Official FDA Materials Page Lists Hyaluronic Acid, Calcium Hydroxylapatite, Poly-L-lactic Acid, and PMMA only. Decellularized allograft adipose matrix is not on the FDA list.
Manufacturer Indication (PI-113) Intended for replacement of damaged or inadequate integumental adipose tissue matrix where native fat would exist, or for supplemental support of underlying adipose matrix.
Labeled Anatomic Contraindications Contraindicated where native adipose tissue does not normally exist and in patients with severe allergy/anaphylaxis history. Manufacturer FAQ explicitly states: never inject into lips, muscle, or breast tissue.
Reversibility Irreversible with Hyaluronidase. Hyaluronidase only breaks down hyaluronic acid. It cannot enzymatically dissolve allograft adipose matrix or newly vascularized adipocytes.
Device Disambiguation Not Renuvion. 510(k) substring hits for renuv are seven Apyx/Bovie helium-plasma handpieces (Product Code GEI, K183610–K230586), not injectable allograft tissue.
Approved U.S. Biostimulators Sculptra (PLLA, PMA P030050), Radiesse (CaHA, PMA P050037 / P050052), and Bellafill (PMMA, PMA P020012).

Is Renuva FDA-approved as a US dermal filler, or regulated as an HCT/P without a PMA?

To understand why commercial claims of "FDA approval" are legally and clinically inaccurate, patients and clinicians must understand the sharp jurisdictional boundary between medical devices regulated by the FDA Center for Devices and Radiological Health (CDRH) and human tissues regulated by the FDA Center for Biologics Evaluation and Research (CBER).

The Premarket Approval (PMA) Hurdle for Dermal Fillers

In the United States, aesthetic injectable dermal fillers—such as Juvéderm, Restylane, Sculptra, and Radiesse—are classified under federal law as Class III medical devices. Class III is the most stringent regulatory tier established under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Because injectable implants are placed into deep dermal, subdermal, or supraperiosteal tissues and remain in the body long-term, the law presumes they present a potential unreasonable risk of illness or injury.

Under 21 U.S.C. § 360e, a Class III medical device cannot be legally commercially distributed without an approved Premarket Approval (PMA) application. A PMA requires the manufacturer to sponsor prospective, randomized, controlled, multi-center human clinical trials demonstrating a "reasonable assurance of safety and effectiveness" for each specific anatomic indication (e.g., correction of moderate to severe facial wrinkles and folds, lip augmentation, or cheek volume deficit).

When the FDA approves a PMA, CDRH publishes a formal Approval Order and an extensive Summary of Safety and Effectiveness Data (SSED). The SSED details the exact number of enrolled patients, primary and secondary endpoint success rates, histological findings, and the incidence of adverse events (such as late-onset inflammatory nodules, granulomas, or vascular compromise).

Regulatory Architecture Comparison:
┌───────────────────────────────────────────────┬───────────────────────────────────────────────┐
│ Class III Dermal Filler Device (PMA / CDRH)   │ Section 361 Human Tissue (HCT/P / CBER)       │
├───────────────────────────────────────────────┼───────────────────────────────────────────────┤
│ • Regulated under FD&C Act § 515 (21 CFR 814) │ • Regulated under PHS Act § 361 (21 CFR 1271) │
│ • Primary Oversight: CDRH (Product Code LMH)  │ • Primary Oversight: CBER (Tissue Safety)     │
│ • Mandates prospective multi-center RCTs      │ • No prospective clinical trials required     │
│ • Generates public SSED and Approval Order    │ • No SSED, no approval letter, no PMA number  │
│ • Grants specific, labeled anatomic claims    │ • Limited to homologous use (basic function)  │
│ • Premarket approval REQUIRED before sale     │ • Postmarket compliance; register & list only │
└───────────────────────────────────────────────┴───────────────────────────────────────────────┘

The FDA Premarket Approval Database Census

A direct audit of the FDA CDRH Premarket Approval database—spanning 56,765 total PMA records with decision dates through 10 July 2026—demonstrates that Renuva has never undergone or received Premarket Approval:

FDA Premarket Approval (PMA) Database Audit:
Total PMA Records in Database: 56,765
Product Code LMH (Dermal Implant, Aesthetic Use): 1,046 records
Product Code PKY (Dermal Implant for Hand Augmentation): 2 records
Queries Run: "Renuva", "Allograft Adipose", "MTF Biologics", "Musculoskeletal Transplant", "AlloClae", "Lipoderma"
Matching Dermal Filler PMA Records Found: 0

Across all 1,046 product-code LMH records in that census—original orders and supplements under the dermal-implant code the FDA fillers page tells readers to search—not a single record belongs to Renuva or MTF Biologics. The only two records under Product Code PKY are P040024/S099 (Restylane Lyft for hand augmentation, approved 18 May 2018) and P050052/S049 (Radiesse for hand augmentation, approved 4 June 2015). For deeper analysis of the hand-filler regulatory landscape, see our comparative guide to dermal fillers for hands.

Furthermore, searching the broader PMA database for the commercial entity Tiger Aesthetics Medical LLC (the distributor of sibling allograft adipose matrix AlloClae) yields only approvals for Bellafill (PMA P020012, polymethylmethacrylate microspheres) and Sientra silicone breast implants (PMA P070004). AlloClae holds zero PMA approvals as a dermal filler.

The FDA Official Dermal Fillers Registry

The FDA CDRH maintains an educational reference registry titled FDA-Approved Dermal Fillers (page last updated 9 November 2020). The agency categorizes all approved injectable filler materials into two groups:

  1. Absorbable (Temporary) Materials:
    • Hyaluronic Acid: Glycosaminoglycan polymers naturally present in human connective tissue, enzymatically degradable with hyaluronidase (e.g., Juvéderm, Restylane, Belotero, RHA).
    • Calcium Hydroxylapatite: Mineral microparticles suspended in an aqueous carboxymethylcellulose gel carrier (Radiesse).
    • Poly-L-lactic Acid: Biodegradable synthetic polymer microparticles that induce host neocollagenesis over several months (Sculptra).
  2. Non-Absorbable (Permanent) Materials:
    • Polymethylmethacrylate (PMMA): Non-resorbable synthetic microspheres suspended in bovine collagen (Bellafill, detailed in our guide to permanent PMMA filler).

Allograft adipose matrix is completely absent from the FDA list. The FDA's materials overview is a class-level explanation, not a complete 2026 product table; newer HA formulations have received PMAs since 2020 (such as Evolysse under PMA P240022, analyzed in our review of new dermal fillers). Those later HA rows still do not create an allograft-adipose filler PMA.

Does CBER donor screening, AATB processing, or a 361 registration make Renuva an approved filler?

A frequent source of patient confusion stems from clinic marketing asserting that because Renuva is "regulated by the FDA" and processed by an American Association of Tissue Banks (AATB) accredited facility, it is therefore "FDA approved."

This is a fundamental conflation of communicable disease compliance with premarket clinical efficacy approval.

The Four "Section 361" Criteria Under 21 CFR 1271.10(a)

Renuva is distributed under the regulatory framework of Section 361 of the Public Health Service Act. Under 21 CFR 1271.10(a), an HCT/P is regulated solely under Section 361 and Part 1271—meaning it is exempt from premarket approval, investigational new drug (IND) requirements, and premarket device clearance—if and only if it meets all four of the following criteria:

  1. Minimal Manipulation: The processing of the tissue does not alter the original relevant characteristics of the tissue relating to the tissue's utility for reconstruction, repair, or replacement. The FDA's July 2020 guidance (Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use) treats adipose as structural tissue and classifies enzymatic isolation of stromal vascular fraction (SVF) as more than minimal manipulation. Whether a given adipose extracellular-matrix product is only minimally manipulated is a processing-and-labeling determination, not a brand-name blessing.
  2. Homologous Use Only: The tissue is intended to perform the same basic function or functions in the recipient as in the donor. For adipose tissue, the FDA interprets the basic function as providing structural support, cushioning, and filling space where subcutaneous fat normally exists. Crucially, the FDA determines homologous use based on the manufacturer's labeling, advertising, and objective marketing intent.
  3. No Combination With Other Articles: The tissue is not combined with another article, such as a drug, synthetic polymer, or biological component, except for water, crystalloids, or sterilizing, preserving, or storage agents that do not raise new clinical safety questions.
  4. Living Cells and Systemic Effect Limits: The tissue either:
    • Does not have a systemic effect and does not depend upon the metabolic activity of living cells for its primary function (Renuva is marketed as an acellular adipose matrix, not as a live-cell SVF or exosome product); OR
    • If it depends on living cells, is intended for autologous use or allogeneic use in a first-degree or second-degree blood relative.
Section 361 HCT/P Exemption Pathway (21 CFR 1271.10):
┌─────────────────────────────────────────────────────────────────────────────┐
│ 1. Is the tissue minimally manipulated? (Matrix preserved, no SVF digestion)│
│    └── YES ──► Continue evaluation                                          │
│ 2. Is it intended for homologous use only? (Space-filling / cushioning)     │
│    └── YES ──► Continue evaluation                                          │
│ 3. Is it uncombined with drugs, synthetics, or active biologics?            │
│    └── YES ──► Continue evaluation                                          │
│ 4. Does it operate without depending on living donor cell metabolism?       │
│    └── YES ──► Regulated SOLELY under PHS Act § 361 / 21 CFR Part 1271     │
│                                                                             │
│ CONSEQUENCE:                                                                │
│ • Mandatory: Establishment Registration (FDA Form 3356)                     │
│ • Mandatory: Donor Eligibility Screening & Infectious Disease Testing       │
│ • Mandatory: Current Good Tissue Practices (cGTPs)                          │
│ • EXEMPT: No Premarket Approval (PMA) application                           │
│ • EXEMPT: No Clinical Trial Safety/Efficacy Review                          │
│ • EXEMPT: No FDA Marketing "Approval" Granted                               │
└─────────────────────────────────────────────────────────────────────────────┘

When an establishment satisfies these four criteria, it must submit an electronic registration and listing to the FDA Center for Biologics Evaluation and Research (CBER) using FDA Form 3356. It must comply with Current Good Tissue Practices (cGTPs) under 21 CFR Part 1271 Subpart D, and conduct comprehensive donor eligibility screening and infectious disease testing under Subpart C (testing for HIV-1/2, Hepatitis B, Hepatitis C, Syphilis, and other transmissible pathogens).

However, CBER tissue registration is not an FDA approval. As CBER notes in its public guidance on Tissue & Tissue Products, the FDA does not evaluate the clinical efficacy, aesthetic results, or longevity of 361 HCT/Ps prior to commercial marketing. The registration simply notifies the agency of the facility's existence and subjects it to routine sanitary inspection.

Package Insert PI-113: The Manufacturer's Actual Label

The legal reality of Renuva's status is spelled out in MTF Biologics' official product documentation: Package Insert PI-113 Rev 8 (April 2020).

Unlike a Class III dermal filler Instructions for Use (IFU)—which defines validated injection depths, clinical response rates on the Validated Wrinkle Severity Rating Scale (WSRS), and prospective complication rates—PI-113 reads as a tissue-bank release document:

  1. Product Description: PI-113 identifies Renuva as donated human tissue that is aseptically processed, passes USP <71> sterility tests, and is not terminally sterilized. The process is described as preserving the extracellular matrix of the allograft adipose so the resulting allograft can serve as a framework for cellular repopulation and vascularization.
  2. Indication for Use: PI-113 specifies that Renuva is intended for:

    "the replacement of damaged or inadequate integumental adipose tissue matrix in areas of the body where native fat would exist." It may also be used "for the reinforcement or supplemental support in underlying adipose tissue matrix as the result of damage or naturally occurring defects."

  3. Explicit Contraindications:
    • "Renuva Allograft Adipose Matrix should not be placed in an area where native adipose does not normally exist."
    • "Renuva Allograft Adipose Matrix is contraindicated for patients with significant allergies manifested by a history of anaphylaxis or severe allergen sensitivity."
  4. Severe Warnings:
    • Residual Infection Transmission Risk: Because the tissue is aseptically processed rather than terminally sterilized, PI-113 warns: "Transmission of infectious diseases may occur despite careful donor selection and laboratory testing, including serology and nucleic acid testing (NAT)."
    • Unevaluated Combinations: The insert states that combining Renuva with autologous lipoaspirate has not been evaluated, and that combining it with local anesthetic agents such as lidocaine has not been evaluated.

On its consumer education portal (myrenuva.com/faq), MTF Biologics stays inside that tissue-bank frame:

"Renuva has passed rigorous safety testing, and is regulated as an HCT/P by the FDA for use anywhere in the body where fat exists."

Separately, the same FAQ states:

"Renuva should never be injected into the lips, muscle, or breast tissue."

The manufacturer itself never claims Renuva is an "FDA-approved dermal filler." It correctly identifies the product as a 361 HCT/P.

Why do clinic pages say FDA-approved, and did January 2021 add Renuva to an FDA injectable list?

If neither the FDA nor MTF Biologics claims Renuva is an approved dermal filler, why do ranking clinic pages still say that it is?

An audit of organic search results identifies three primary sources of commercial misinformation:

1. The Mythical "January 2021 FDA Approval"

One of the most persistent claims appears on aesthetic clinic blogs, exemplified by Birmingham, Michigan's AMAE Med Spa (birminghammedspa.com):

"In January 2021, Renuva was added to the list of FDA-approved injectable products that volumize the face and body."

This statement does not match the federal record. A complete audit of CDRH Premarket Approval orders and 510(k) clearances in January 2021 demonstrates that:

  • Zero PMA orders were issued to MTF Biologics, Musculoskeletal Transplant Foundation, or Renuva;
  • Zero 510(k) clearances were granted for any adipose matrix or soft-tissue injectable bearing the name Renuva;
  • The official FDA-Approved Dermal Fillers webpage was not modified in January 2021 (its last modification date remains 9 November 2020).

Those databases contain no matching January 2021 Renuva trade name. The likeliest reading is that clinic copy conflated commercial promotion of an HCT/P—MTF already positions Renuva as an "off-the-shelf alternative to autologous fat transfer"—with an FDA filler approval. That conflation is the error. This page does not reconstruct an unpublished 2021 marketing calendar.

2. Clinical Grouping and Classification Errors

Prominent plastic surgery practices frequently misclassify Renuva in their website navigation menus, inadvertently misleading prospective patients:

  • Ghavami Plastic Surgery (Beverly Hills, CA): Ranks prominently for Renuva queries but files Renuva directly under its /injectables/dermal-fillers/renuva/ directory (ghavamiplasticsurgery.com). The page describes Renuva as an "FDA-approved injectable" and lists breasts, hips, and buttocks among its treatment areas—directly contradicting MTF Biologics' explicit instruction that Renuva must never be injected into breast tissue.
  • Aesthetx (Menlo Park, CA): Ranks in the top three organic results (aesthetx.com). The lead calls Renuva "FDA-approved" and says it has undergone rigorous testing "for use in areas where fat naturally exists." The same lead mentions breasts and buttocks; later text on the same page cautions that Renuva is "not suitable for injection into muscles, lips, or breast tissue," illustrating internal editorial contradictions.
  • American Society of Plastic Surgeons (ASPS): In an article titled Understanding fat-based fillers: alloClae, Renuva, Lipoderma and more (plasticsurgery.org), the society groups Renuva into a broad "fat-based filler" category and casually refers to sibling product alloClae as "FDA-approved." While professional societies frequently create broad procedural categories for patient education, grouping a 361 tissue into a "filler" article does not confer Class III PMA regulatory status.

3. Allure's Independent Journalism vs. Clinic Copy

The closest accurate mainstream media coverage is found in Allure (allure.com/story/renuva-regenerative-injectable). Allure correctly clarifies that the FDA regulates Renuva as an HCT/P—a distinct CBER process that differs completely from dermal fillers and neurotoxins—and notes that sibling product AlloClae is "FDA-compliant" because Section 361 products do not require premarket approval prior to commercialization.

However, Allure's reporting does not audit the CDRH PMA census, does not disambiguate 510(k) false positives, and cites commercial clinic quotes of upwards of $1,500 per 1.5 cc syringe as standard consumer pricing.

Is Renuvion a 510(k) for Renuva, or a different Apyx plasma device?

When savvy consumers search the FDA's public databases for Renuva clearances, they frequently encounter official FDA clearance letters bearing the name Renuvion. This creates a serious false-positive assumption that Renuva possesses an FDA 510(k) premarket clearance.

An analysis of the FDA 510(k) Premarket Notification database (175,559 total clearance records through July 2026) reveals that Renuva has zero 510(k) clearances.

The substring "renuv" in the device-name field returns exactly eight records, none of which is Renuva:

FDA 510(k) Database Substring Audit ("renuv"):
Total Clearance Records in Database: 175,559
Records Matching Substring "renuv": 8

1. K183610 (Cleared 2019-03-12): Renuvion/J-Plasma Precise Handpiece (Bovie Medical, Code GEI)
2. K191484 (Cleared 2019-07-30): Renuvion/J-Plasma Precise Handpiece (Apyx Medical, formerly Bovie, Code GEI)
3. K211652 (Cleared 2022-05-25): Renuvion Dermal Handpiece / Dermal System (Apyx Medical, Code GEI)
4. K220970 (Cleared 2022-07-15): Renuvion APR Handpiece (Apyx Medical, Code GEI)
5. K223262 (Cleared 2023-02-23): Renuvion APR Handpiece (Apyx Medical, Code GEI)
6. K230272 (Cleared 2023-04-27): Renuvion APR Handpiece (Apyx Medical, Code GEI)
7. K230586 (Cleared 2023-06-09): Renuvion Micro Handpiece (Apyx Medical, Code GEI)
8. K242825 (Cleared 2025-01-17): Prenuvo Body Composition Software (Prenuvo, Code LNH)

Seven of these records represent Renuvion (formerly known as J-Plasma), manufactured by Apyx Medical Corporation (Clearwater, FL; earlier filings used Bovie Medical). Renuvion is an electrosurgical device regulated under Product Code GEI (Electrosurgical, cutting & coagulation & accessories). It delivers helium plasma and radiofrequency energy through a surgical cannula to achieve sub-dermal soft tissue coagulation. It is an energy-based surgical tool, not an injectable matrix. For safety warnings regarding plasma devices, consult our guide to Renuvion J-Plasma risks and FDA warnings.

The eighth record is an artificial intelligence radiological tool (Prenuvo) under Product Code LNH.

Furthermore, an applicant query for Musculoskeletal Transplant Foundation in the 510(k) database returns solely orthopedic bone void fillers, demineralized bone matrix (DBM), and spinal fixation devices (e.g., K081512, K191060). MTF holds zero 510(k) clearances for aesthetic injectable products.

Device Identity Disambiguation:
┌───────────────────────────────────────────────┬───────────────────────────────────────────────┐
│ Renuva Allograft Adipose Matrix               │ Renuvion APR / J-Plasma System                │
├───────────────────────────────────────────────┼───────────────────────────────────────────────┤
│ • Manufacturer: MTF Biologics                 │ • Manufacturer: Apyx Medical Corporation      │
│ • Classification: 361 HCT/P Tissue (CBER)     │ • Classification: Class II Medical Device     │
│ • Product Code: None (Tissue Registration)    │ • Product Code: GEI (Electrosurgical Device)  │
│ • Form: Injectable adipose matrix         │ • Form: Helium plasma / RF surgical generator │
│ • Clearance/Approval: None (361 HCT/P)    │ • Clearance/Approval: 510(k) (K223262, etc.)  │
│ • Clinical Purpose: Volume via fat matrix │ • Clinical Purpose: Soft-tissue coagulation   │
└───────────────────────────────────────────────┴───────────────────────────────────────────────┘

How does Renuva differ from Sculptra, Radiesse, Bellafill, HA fillers, and surgical fat grafting?

Patients seeking facial rejuvenation or body contouring are often presented with Renuva alongside traditional dermal fillers, biostimulators, and autologous fat transfer. Understanding how Renuva's biological mechanism and regulatory status compare to FDA-approved alternatives is critical for informed consent.

Comprehensive Injectable Volumizer & Biostimulator Comparison:
┌───────────────┬──────────────────────┬──────────────────────┬──────────────────────┬──────────────────────┐
│ Product /     │ Regulatory Status    │ Primary Composition  │ Mechanism of Action  │ Enzymatic Reversal / │
│ Procedure     │ & Product Code       │ & Active Agent       │ & Degradation Fate   │ Clinical Recourse    │
├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
│ **Renuva**    │ **361 HCT/P Tissue** │ Donor adipose        │ Acellular matrix     │ **Irreversible.**    │
│               │ (PHS Act § 361;      │ extracellular matrix │ acts as scaffold;    │ Cannot be dissolved  │
│               │ CBER listing only;   │ (manufacturer:       │ host cells migrate    │ with hyaluronidase.  │
│               │ NO PMA / NO 510k)    │ collagens, proteins, │ in over months        │                      │
│               │                      │ growth factors)      │                      │                      │
├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
│ **Sculptra**  │ **Class III PMA**    │ Synthetic poly-      │ Foreign-body macro-  │ **Irreversible.**    │
│               │ (CDRH Code LMH;      │ L-lactic acid (PLLA) │ phage response; host │ Cannot be dissolved  │
│               │ PMA P030050,         │ microparticles in    │ neocollagenesis      │ with hyaluronidase;  │
│               │ Orig. 2004-08-03)    │ carboxymethylcellulose│ over 6–12 months     │ requires nodule      │
│               │                      │                      │                      │ management.          │
├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
│ **Radiesse**  │ **Class III PMA**    │ Synthetic calcium    │ Immediate CMC gel    │ **Irreversible.**    │
│               │ (CDRH Codes LMH/PKY; │ hydroxylapatite      │ volume; CaHA micros- │ Cannot be dissolved  │
│               │ PMA P050037/P050052, │ (CaHA) microspheres  │ pheres stimulate     │ with hyaluronidase;  │
│               │ Orig. 2006-12-22)    │ (30%) in CMC gel     │ collagen and elastin │ sodium thiosulfate   │
│               │                      │                      │                      │ experimental only.   │
├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
│ **Bellafill** │ **Class III PMA**    │ Non-resorbable PMMA  │ Immediate collagen   │ **Irreversible.**    │
│               │ (CDRH Code LMH;      │ microspheres (20%)   │ volume; PMMA spheres │ Permanent synthetic  │
│               │ PMA P020012,         │ in bovine collagen   │ permanently encapsulate│ material; requires │
│               │ Orig. 2006-10-27)    │ gel carrier (80%)    │ host fibrous tissue  │ surgical excision.   │
├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
│ **HA Fillers**│ **Class III PMA**    │ Cross-linked sodium  │ Space-occupying water│ **Reversible.**      │
│ (Juvéderm,    │ (CDRH Codes LMH/PKY; │ hyaluronate          │ binding; degraded    │ Readily dissolved    │
│ Restylane)    │ e.g., P050047,       │ hydrogel matrix      │ by endogenous        │ with injectable      │
│               │ P040024, P110033)    │                      │ hyaluronidases       │ hyaluronidase enzyme.│
├───────────────┼──────────────────────┼──────────────────────┼──────────────────────┼──────────────────────┤
│ **Autologous  │ **Surgical Tissue**  │ Patient's own living │ Harvested, processed, │ **Irreversible.**    │
│ Fat Grafting**│ (Exempt surgical     │ adipocytes and       │ and reinjected fat;   │ Living fat cells;    │
│               │ procedure; same-     │ supporting tissue    │ retention varies and  │ can enlarge with     │
│               │ day autologous use)  │                      │ is not a PMA label    │ weight gain.         │
└───────────────┴──────────────────────┴──────────────────────┴──────────────────────┴──────────────────────┘

1. Mechanism of Action: Scaffold vs. Inflammatory Stimulation

Traditional biostimulators—such as Sculptra (PLLA) and Radiesse (CaHA)—operate by triggering a controlled, sub-clinical sub-inflammatory foreign-body reaction. As host macrophages engulf the synthetic microparticles, fibroblasts are recruited to deposit Type I and Type III collagen. For details on how PLLA stimulates neocollagenesis over time, consult our clinical guide to how long Sculptra takes to work. For comparison between the two major biostimulators, see Sculptra vs. Radiesse and Sculptra vs. traditional filler.

In contrast, Renuva contains no synthetic polymer microspheres. MTF describes it as an extracellular-matrix allograft containing collagens, proteins, and growth factors found in adipose tissue. When injected where native fat exists, the manufacturer positions it as an inductive scaffold: host cells and vessels populate the matrix over months, and the donor matrix is meant to be replaced by the patient's own tissue. The consumer FAQ says the matrix is eliminated over about three to six months, leaving the patient's own fat.

That is a manufacturer mechanism claim plus supporting literature, not a PMA SSED. Kokai et al. (Plastic and Reconstructive Surgery, 2019; PMID 30688888) reported adipogenic remodeling in a nude-mouse and human histology model. Gold et al. (Journal of Cosmetic Dermatology, 2020; PMID 32176417) reported a multicenter open-label temple pilot with at least six-month volume retention. Neither paper is a Class III filler approval, and neither should be read as a labeled duration.

2. The Permanence and Longevity Myth

Commercial med spas frequently advertise Renuva as lasting "up to 10 years" or being "permanent." The manufacturer FAQ frames duration as the biology of fat cells: "research findings suggest that human fat cells can last up to 10 years." Dr. Michael Gold published an eight-year follow-up of a single patient (n=1) in Dermatologic Surgery (2024; PMC12036727) describing persistent correction of steroid-induced buttock atrophy after allograft adipose matrix injection. Gold is a consultant for MTF Biologics; an MTF coauthor is listed.

However, an n=1 case report and marketing claims of 10-year fat longevity do not constitute an FDA-approved duration claim.

  • Unlike Radiesse (which possesses validated clinical duration data through 12–18 months in its SSED, reviewed in how long Radiesse lasts) or Bellafill (which established 5-year safety and retention in prospective multi-center PMA trials), Renuva has zero prospective, randomized PMA trial data evaluating duration.
  • Newly established adipocytes behave exactly like native fat cells: if the patient undergoes significant weight loss, develops an illness, or initiates GLP-1 receptor agonist therapy (such as semaglutide or tirzepatide), the fat cells will lose lipid volume and shrink. For treatment strategies addressing medication-induced fat depletion, see our clinical review of GLP-1 Ozempic face treatments.
  • Conversely, if the patient experiences substantial systemic weight gain, the newly established adipocytes can hypertrophy, potentially leading to localized asymmetry or contour irregularities.

3. Comparison with Surgical Autologous Fat Grafting

MTF Biologics positions Renuva as an "off-the-shelf alternative to autologous fat transfer." While autologous fat grafting requires liposuction to harvest the patient's own fat, followed by centrifugation and reinjection, Renuva eliminates the donor-site surgical morbidity, bruising, and recovery.

However, autologous fat transfer provides a large volume of the patient's own living cells in a single surgical sitting. Renuva is sold in 1.5 cc and 3 cc syringes. Using it for large-volume buttock enhancement or breast reconstruction would mean many syringes and would run into the manufacturer's never-breast line. For surgical fat as the alternative, see autologous fat grafting survival and cost.

4. Irreversibility and Vascular Safety

The most critical clinical safety fact for prospective patients is that Renuva cannot be dissolved with hyaluronidase.

With hyaluronic acid dermal fillers, an injector can immediately reverse overfilling, asymmetry, or an acute intra-arterial vascular occlusion by injecting ovine or recombinant human hyaluronidase, which enzymatically cleaves the filler matrix (detailed in our guide to dissolving filler with hyaluronidase).

Renuva contains zero hyaluronic acid. Hyaluronidase has no enzymatic activity against allograft adipose matrix or host fat cells:

  • If product is accidentally injected into a facial artery, it can cause mechanical vascular occlusion, with risks that include tissue injury and vision loss. For how that emergency is recognized—not a treatment protocol—see filler vascular occlusion.
  • If product is placed too superficially, it can create visible or palpable irregularities that cannot be dissolved with hyaluronidase. That is a reason to prefer a reversible HA filler when the patient wants an enzymatic off-ramp; it is not a reason to improvise an in-office dissolving recipe.

Who should skip a Renuva quote (FDA-approved-filler claim, lips or breast, hyaluronidase reversal, Renuvion mix-up)?

Prospective aesthetic patients should exercise extreme caution when evaluating Renuva. You should decline or skip a Renuva quote if any of the following clinical, regulatory, or ethical red flags occur:

Renuva Quote Decision Framework:
┌────────────────────────────────────────────────────────────┬────────────────────────┐
│ Clinical Scenario / Injector Statement                    │ Recommended Decision   │
├────────────────────────────────────────────────────────────┼────────────────────────┤
│ • Injector claims Renuva is an "FDA-approved dermal filler"│ ❌ DECLINE QUOTE       │
│ • Clinic asserts Renuva was added to an FDA list in 2021   │ ❌ DECLINE QUOTE       │
│ • Provider offers Renuva for lips, breasts, or large BBL   │ ❌ DECLINE QUOTE       │
│ • Patient requires an enzymatically reversible filler      │ ❌ DECLINE QUOTE       │
│ • Practice conflates Renuva with Renuvion plasma device    │ ❌ DECLINE QUOTE       │
│ • Patient undergoing active GLP-1 / systemic weight loss   │ ⚠️ POSTPONE TREATMENT   │
│ • Small-volume deficit (temples, hands, contour dips)      │ ⚖️ CONSIDER ALTERNATIVES│
│   quoted by an experienced MD with full HCT/P disclosure   │ (Sculptra / Radiesse)  │
└────────────────────────────────────────────────────────────┴────────────────────────┘

1. The Provider Claims Renuva is an "FDA-Approved Dermal Filler"

If a medical spa, dermatologist, or plastic surgeon tells you that Renuva is an FDA-approved dermal filler or cites a "January 2021 FDA injectable approval list," walk away. A provider who misrepresents a Section 361 HCT/P tissue as a Class III PMA medical device either does not understand federal medical device law or is intentionally misleading you. Informed consent requires absolute truth regarding regulatory clearance.

2. The Provider Offers Injection into Lips, Breasts, or Large Body Contours

MTF Biologics' consumer FAQ and Package Insert PI-113 explicitly mandate:

  • Never inject into the lips: The lips consist of dense orbicularis oris muscle covered by vermilion mucosa. Native subcutaneous adipose tissue does not exist in the superficial mucosal lip; injecting allograft fat matrix into lips violates PI-113 contraindications and carries high risks of chronic, palpable nodules. For lip augmentation, always choose FDA-approved HA fillers.
  • Never inject into the breasts: While the FDA's general guidance on homologous tissue mentions that fat transplantation can cushion breast tissue in reconstructive surgery, MTF Biologics explicitly forbids cosmetic breast injections with Renuva. Injecting allograft matrix into the breast parenchyma can cause microcalcifications, oil cysts, and fat necrosis that mimic breast carcinoma on screening mammography.
  • Never use for large-volume Brazilian Butt Lift (BBL) augmentation: Injecting large volumes of any particulate or matrix into the deep gluteal tissues carries catastrophic risks of fatal fat embolism. While small contour defects or cellulite dimples are within the manufacturer's suggested scope, large-volume body shaping should never be attempted. For lateral pelvic hollows, consult our guide to hip dips filler anatomy and safety.

3. You Want a Reversible Treatment

If you have never received facial injectables, are anxious about aesthetic outcomes, or want the safety net of an antidote, Renuva is a poor fit. Only hyaluronic acid fillers can be dissolved with hyaluronidase. Overfilling tear troughs, temples, or cheeks with an irreversible matrix is not a hyaluronidase problem. For temple hollows, consider FDA-approved options in temple filler anatomy, safety, and cost.

4. You Are Actively Losing Weight (or on GLP-1 Medications)

Renuva relies on host adipose biology. If you are in an active fat-loss phase or taking a GLP-1 receptor agonist, a matrix that is supposed to recruit fat is a poor match for the physiology in the room. Ask the injector how they would time treatment relative to weight change; this page does not set a waiting period. For the GLP-1 volume-loss cluster, see GLP-1 Ozempic face treatments.

5. Opacity Regarding Procedure Costs

Because Renuva is not an FDA-approved medical device, there is no standardized manufacturer list price. The consumer FAQ says cost varies by injector and geography. Allure reported clinic quotes upwards of $1,500 per 1.5 cc syringe as journalism, not a label. Ask for a written quote in cubic centimeters. Do not treat a spa package price as an FDA fee schedule.

Frequently Asked Questions

Is Renuva FDA-approved in the United States?

No. Renuva is not an FDA-approved dermal filler. It is regulated as a Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) under Section 361 of the Public Health Service Act and 21 CFR Part 1271. In a comprehensive census of all 1,046 Class III dermal implant records under FDA Product Code LMH through July 2026, Renuva holds zero Premarket Approvals (PMA). The official FDA-Approved Dermal Fillers materials list contains hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, and PMMA; decellularized allograft adipose matrix is not on the list.

Is Renuva a dermal filler like Juvéderm or Sculptra?

No. Juvéderm is a hyaluronic acid gel and Sculptra is synthetic poly-L-lactic acid; both are Class III medical devices that underwent extensive prospective human clinical trials to earn FDA Premarket Approval. Renuva is an acellular extracellular matrix derived from donated human cadaveric fat tissue. It operates as an inductive tissue graft that recruits host adipocytes, rather than an FDA-approved medical device.

Can Renuva be dissolved with hyaluronidase?

No. Hyaluronidase hydrolyzes hyaluronic acid. Renuva contains no hyaluronic acid; the manufacturer describes collagens, proteins, and growth factors from donor adipose matrix. Hyaluronidase has no enzymatic effect on that matrix or on native fat cells it may recruit. Inadvertent vascular occlusion or misplaced product cannot be reversed with hyaluronidase.

Is Renuva the same as Renuvion?

No. Renuva and Renuvion are entirely different products manufactured by different companies. Renuva is an injectable allograft fat matrix manufactured by MTF Biologics. Renuvion (formerly J-Plasma) is an electrosurgical device manufactured by Apyx Medical Corporation that delivers helium plasma and radiofrequency energy to coagulate subdermal tissue. Renuvion holds multiple FDA 510(k) clearances under Product Code GEI (such as K223262), but those clearances have no connection to Renuva.

Is Renuva better than Sculptra or fat transfer?

Renuva is neither better nor worse; it serves a different clinical niche with distinct legal and biological tradeoffs. Sculptra is an FDA-approved Class III biostimulator (PMA P030050) with a public SSED, but it generates fibrous collagen rather than fat. Autologous fat transfer uses your own living fat, but requires surgical harvest. Renuva is an off-the-shelf adipose matrix without a filler PMA, cannot be dissolved with hyaluronidase, carries a residual donor-tissue infection warning, and has no labeled US list price. For the labeled US PLLA-versus-CaHA shopping decision, see Sculptra vs. Radiesse. For CE-marked PCL that also lacks a US filler PMA, see Is Ellansé FDA-approved?. For US-approved PLLA used off-label on the buttocks, see Is Sculptra FDA-approved for the buttocks?.

Why do some clinics say Renuva was FDA-approved in 2021?

In early 2021, some clinic pages began repeating that Renuva had been "added to the FDA approved injectable list in January 2021." No matching PMA or 510(k) trade name exists in the census for that month, and the FDA materials page was not updated then. The sentence conflates HCT/P marketing with a filler approval. Federal databases confirm zero PMA or 510(k) records for Renuva in January 2021 or later through 10 July 2026.

What to Ask If a Clinic Quotes Renuva

If you consult with an aesthetic medical practice in the United States and the clinician recommends or offers Renuva, protect your safety and financial investment by asking these five direct questions:

  1. "Are you treating Renuva as a Section 361 HCT/P tissue graft, and can you confirm it does NOT hold an FDA Premarket Approval (PMA) as a dermal filler?"
    Why to ask: Determines whether the injector is being transparent about regulatory status or repeating marketing claims that conflate tissue registration with Class III device approval.
  2. "Can we review MTF Biologics' Package Insert PI-113 together, specifically the contraindication against injecting areas where native fat does not exist?"
    Why to ask: Ensures the injector is adhering to manufacturer safety boundaries and will not inject Renuva into mucosal lips, muscle, or breast tissue.
  3. "What is your plan if an accidental vascular occlusion occurs, given that Renuva cannot be dissolved with hyaluronidase?"
    Why to ask: Confirms the practice understands irreversibility and can explain how they would recognize and escalate a vascular event—not a protocol for you to follow at home.
  4. "Why is Renuva the better tool for this specific hollow compared with FDA-approved alternatives like Sculptra (PMA P030050) or Radiesse (PMA P050052)?"
    Why to ask: Forces the injector to justify using a 361 tissue allograft rather than a Class III biostimulator that has a public SSED.
  5. "What is the exact volume in cubic centimeters being injected, what is the cost per syringe, and what happens if I lose weight over the next two years?"
    Why to ask: Protects you from vague package pricing and makes the weight-sensitivity of newly established adipocytes explicit.

For broader clinical guidance on off-label aesthetic injections, informed consent standards, and biologic safety, explore our reference guides to off-label aesthetic injections and unapproved regenerative aesthetics and exosomes.

Sources

Topics
Dermal FillersBiostimulatorsSculptraSafetyRegulatoryCost
Ran Chen
Contributing Editor
Ran Chen

Founder, AestheticMedGuide. Life-sciences operator covering aesthetic devices, injectables, and the industry behind them. Previously global market-access lead across pharma and medtech.

Follow on LinkedIn →

Keep reading from Injectables

See all →
Injectables · 30 min read

Is Ellanse FDA-Approved? PCL Suture Clearance Is Not a Dermal-Filler PMA

Ellanse is a CE-marked PCL biostimulator, not a US PMA filler. Clinic pages that call it FDA-approved mix suture polymer uses with Sculptra HIV…

Injectables · 27 min read

Is Sculptra FDA-Approved for the Buttocks? Three Face Indications, Zero Gluteal PMA

US Sculptra is PMA P030050 for face only: HIV lipoatrophy, nasolabial folds, and cheek wrinkles. A Sculptra butt lift is off-label. Cleveland Clinic…

Injectables · 27 min read

How Long Does Radiesse Last? Area-by-Area PMA Duration, Not One 12-to-18-Month Number

Radiesse duration is PMA- and area-specific. Manufacturer up-to-2-years is not the SSED table. Décolleté 1:2 is labeled; hyperdilute body is not.